Management is buying/committing capital at a price it says the market itself just set against it — cheapness measured ag
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes deliberately taking on more of its own economic exposure because it believes the outside world is mispricing what it already has. The question asks for a coherent posture with both halves: (1) mispricing anchored to something concrete, and (2) acting on it with real resources already in motion. Let's examine the transcript. Management discusses various things: Tyvaso DPI royalty sale, pipeline, Afrezza, etc. They mention selling 1% of Tyvaso royalty for $150M, and they say they didn't sell more because they didn't need to and wanted to preserve 90% of that value for shareholders. They also mention that analysts have expenses for pipeline but no revenue, and they think that's an unfair valuation. They mention insiders picked up stock because they believe they're undervalued. They also mention paying off debt, not accessing ATM, etc. Key points: - They sold 1% of royalty, but they kept 90% (actually 9%? They had 10%, sold 1%, so 9% remains). They say they wanted to preserve 90% of that value for shareholders. That indicates they are retaining exposure because they think it's worth more than what they could get? But they did sell 1% at a valuation of $1.5-2B for the 10% royalty. They didn't sell more because they didn't need to. That's not necessarily mispricing; they just didn't need more cash. They also say "we want to deep risk on the debt side" but that's about debt. - They mention "Analysts have expenses in -- for our pipeline, but no revenue in the next five years. We think this is an unfair valuation of our Company given that we do expect to launch clofazimine in the next five years and move NTM -- I'm sorry, and move the IPF asset in terms of MNKD-201 into patients and then hopefully the Phase 3 by then." That's a claim that the market is undervaluing because analysts don't include pipeline revenue. But is that anchored to something concrete? They mention comparable: InterMune was valued at $800M and later $8B after positive data. That's a comparison, but it's not a concrete benchmark for their own assets. They also mention "every 1,000 patients approximately $100 million in revenue" for MNKD-101, and for MNKD-201 every 1,000 patients is roughly $150 million. That's per-patient revenue estimates, but not a valuation of the company. They also mention insiders picked up stock.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CTHR | Charles & Colvard, Ltd. | Q1 2023 | 2022-11-06 | F |
| SBGI | Sinclair Broadcast Group, Inc. | Q3 2022 | 2022-11-02 | C |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
TWO · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the mispricing to concrete, verifiable levels: mortgage spreads at “historically wide” levels (125–150 bp ZV/OAS, far above the non-QE average and the March 31 levels), RMBS coupons now trading at a wide range (2 %–5.5 %) with 300 bp “out-of-the-money” low-coupon pools and 97 bp OAS–ZV spread differential on higher-coupon names.
ESEA · Q4 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete, verifiable figure: their own estimate of the fleet’s market value at $666 million (derived from charter-adjusted values and market changes, incorporating the Aegean Express incident), which produces a net asset value of $344 million or >$48 per share.
WD · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete benchmark: CoStar trades at ~30x EBITDA while W&D trades at under 10x despite identical revenue and EBITDA growth rates over 5–10 years. They explicitly state there is “plenty of multiple expansion available to W&D.